Biohaven provides update for its inflammatory disease drug; stock falls

 ** Drug developer Biohaven's BHVN.N shares fall 12.9% to $46.24

** Company provides update on ongoing early stage study of its experimental inflammatory disease drug called BHV-1300

** TD Cowen analyst Tyler Van Buren says the drug's starting dose of 10 milligrams is lower than anticipated

** Higher doses than what is being tested in first two cohorts will be required to achieve reductions of 70% or higher in levels of disease causing antibodies called IgG - Buren

** Drug showed IgG reductions of about 80%, seen about two days after a single dose, company says

** BTIG analyst Thomas Shrader says most troublesome issue with BHV-1300 is 5 gram to 20 gram equivalent doses

** "If these doses are required going forward, toxicity readouts will be of great interest" - Shrader

** Drug is safe and well tolerated with no serious adverse events reported, company says

** Including session moves, stock up 5% YTD

https://www.xm.com/research/markets/allNews/reuters/biohaven-provides-update-for-its-inflammatory-disease-drug-stock-falls-53813182